$15.850
+0.070 (+0.44%)收盤時
ANGO 資訊
ANGO 事件
AngioDynamics Receives FDA Approval to Initiate RELIEF Study
AngioDynamics announced that the U.S. Food and Drug Administration, FDA, has approved the Company's Investigational Device Exemption, IDE, application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation, IRE, the non-thermal ablation technology delivered by the Company's NanoKnife System, for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
AngioDynamics Announces Two-Year Results for NanoKnife System
AngioDynamics announced two-year results from the PRESERVE pivotal trial demonstrating durable oncologic control and a sustained safety profile for the NanoKnife System in the focal ablation of intermediate-risk prostate cancer. The data will be discussed by Izak Faiena, M.D., of Columbia University at the 2026 American Urological Association Annual Meeting on Sunday, May 17 in Washington, D.C. The PRESERVE trial is a prospective, single-arm pivotal IDE study evaluating focal irreversible electroporation using the NanoKnife System in 121 patients with Gleason Grade Group 2-3 intermediate-risk prostate cancer, conducted across 17 U.S. clinical centers in collaboration with the Society of Urologic Oncology Clinical Trials Consortium. Primary 12-month results, published in European Urology in July 2025, demonstrated an 80% freedom-from-treatment-failure rate among protocol-biopsied patients. At 24 months, the updated findings confirm durability of outcomes: 94.4% of analysis-eligible patients (68 of 72) completed the 24-month assessment, reflecting strong cohort retention; No new treatment failures were identified among patients with available follow-up at 24 months; One patient (1.5%) underwent a clinically indicated biopsy, which was negative for any cancer; 97% of patients (66 of 68) had a PSA at 24 months below their baseline value; No new device- or procedure-related adverse events were reported between the 12- and 24-month assessments. The 24-month PRESERVE data complement an international long-term evidence base for focal IRE, including median five-year outcomes from a 2023 international multi-institutional cohort demonstrating sustained oncologic control and preservation of functional outcomes.
Major U.S. Averages Mixed as Oil Prices Rise to $111.54
The major averages had a mixed last session of the holiday-shortened week] as traders continue to monitor the war in Iran and rising oil prices after President Donald Trump delivered an address on Wednesday night, during which he said that the U.S. is "getting very close" to ending the war. However, Trump added that the U.S. would "hit" Tehran "extremely hard." Afterward, Trump posted about the war again on social media, saying in a Truth Social post that it's time for Iran to make a deal "before it's too late." Amid the ongoing rhetoric, U.S. crude oil futures settled at $111.54 per barrel, up 11%.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Amazonis in talks to acquire Globalstar,Teslareported 358,023 vehicle deliveries in Q1, which William Blair said was slightlyFordreported anin Q1 U.S. vehicle salesSBA Communicationsis weighing a sale of the company after receiving takeover interest,The White House announced it is imposing 100% tariffs on patented pharmaceutical products and strengthened tariffs on steel, aluminum, and copper imports2. WALL STREET CALLS:Wingstopto Overweight at Piper Sandler and to Strong Buy at Raymond JamesRTXto Buy at Melius ResearchOllie's Bargain Outletto Buy at JefferiesWix.comto Neutral at UBSAkamaito Neutral at Baird3. AROUND THE WEB:Comcast's"Super Mario Galaxy Movie" has had the biggest opening day domestic gross of 2026, Variety reportsHersheywill change the chocolate in a small portion of its Reese's and Hershey's products to use "classic milk and dark chocolate recipes," with the shift to pure chocolate ingredients affecting less than 3% of Reese's products and a sliver of Hershey's products, Bloomberg saysIntelis planning to invest another $15M in SambaNova, a chip startup chaired by Intel CEO Lip-Bu Tan, Reuters saysPublicis Groupeis acquiring sports-marketing agency 160over90 from WME Group for more than $500M, WSJ reportsSam's Club, which is owned by Walmart, said it plans to increase its annual membership fee by $10, offering its one-year basic membership option for $60 and its higher-tier option for $120, CNBC says4. MOVERS:Transoceanincreased after beingPenguin Solutionsgained afterand providing guidance for FY26Intuitive Machineswas higher after34.57M shares of stockTeluswas lower in New York after TD Securitiesthe stock to HoldBCEfell in New York after TD Securitiesthe stock to Hold5. EARNINGS/GUIDANCE:Acuity Brands, with EPS and revenue beating consensusAngioDynamicsand narrowed its guidance for FY26Scotts Miracle-Grobacked itsAirSculpt, with EPS higher year-over-yearBassett Furniture, with EPS and revenue lower year-over-yearINDEXES:The Dow fell 61.07, or 0.13%, to 46,504.67, the Nasdaq gained 38.24, or 0.18%, to 21,879.18, and the S&P 500 advanced 7.37, or 0.11%, to 6,582.69.
Major Averages Decline as Oil Prices Rise
The major averages were lower near noon as traders continue to monitor the war in Iran and increasing oil prices. The top indices came off earlier lows after the Islamic Republic News Agency said that Iran and Oman are drafting a protocol to "monitor" traffic through the Strait of Hormuz. The news comes after President Donald Trump delivered an address on Wednesday night, during which he said that the U.S. is "getting very close" to ending the war, though Trump added that the U.S. would "hit" Tehran "extremely hard." Following the comments, WTI and Brent crude futures both jumped as the U.S. and European benchmarks hold well above $100 per barrel.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Amazonis in talks to acquire Globalstar,Teslareported 358,023 vehicle deliveries in Q1, which William Blair said wasFordreported anin Q1 U.S. vehicle salesImmunovantsaid its two Phase 3 studies of batoclimab failed toFollowing President Trump's address last night, shares of energy companies like BPand Chevronwhile travel stocks, including Carnivaland JetBlue, were slipping2. WALL STREET CALLS:Wingstopto Overweight at Piper Sandler and to Strong Buy at Raymond JamesRTXto Buy at Melius ResearchOllie's Bargain Outletto Buy at JefferiesWix.comto Neutral at UBSAkamaito Neutral at Baird3. AROUND THE WEB:Hershey (HSY) will change the chocolate in a small portion of its Reese's and Hershey's products to use "classic milk and dark chocolate recipes," with the shift to pure chocolate ingredients affecting less than 3% of Reese's products and a sliver of Hershey's products, Bloomberg saysGoogleis developing a fitness band meant to compete with wearable devices from upstarts such as Whoop and Oura Health Oy, Bloomberg reportsIntelis planning to invest another $15M in SambaNova, a chip startup chaired by Intel CEO Lip-Bu Tan, Reuters saysPublicis Groupeis acquiring sports-marketing agency 160over90 from WME Group for more than $500M, WSJ reportsSam's Club, which is owned by Walmart, said it plans to increase its annual membership fee by $10, offering its one-year basic membership option for $60 and its higher-tier option for $120, CNBC says4. MOVERS:Transoceanincreases after beingPenguin Solutionsgains afterand providing guidance for FY26Intuitive Machineshigher after34.57M shares of stockTeluslower in New York after TD Securitiesthe stock to HoldBCElower in New York after TD Securitiesthe stock to Hold5. EARNINGS/GUIDANCE:Acuity Brands, with EPS and revenue beating consensusAngioDynamicsand narrowed its guidance for FY26Scotts Miracle-Grofor FY26AirSculpt, with EPS higher year-over-yearBassett Furniture (BSET), with EPS and revenue lower year-over-yearINDEXES:Near midday, the Dow was down 0.43%, or 199.23, to 46,366.51, the Nasdaq was down 0.33%, or 71.90, to 21,769.05, and the S&P 500 was down 0.26%, or 17.14, to 6,558.18.
Company Reports Q3 Revenue of $78.4M, Beating Expectations
Reports Q3 revenue $78.4M, consensus $76.77M. "We delivered a strong quarter, driven by continued execution across the organization, allowing us to deliver yet another quarter of profitable growth," commented CEO Jim Clemmer. "Our mechanical thrombectomy portfolio exhibited standout performance as commercial adoption continues to build with both AlphaVac and AngioVac, confirming our belief that we have the strongest mechanical thrombectomy portfolio available. Auryon remains a consistent growth driver, and NanoKnife is accelerating adoption as we see our commercial strategy supported by the recently effective CPT 1 code for prostate. Beyond the demonstrated topline growth in our higher margin Med Tech businesses, the disciplined execution of our operating initiatives translated into another quarter of strong positive adjusted EBITDA. Our year-to-date performance gives us confidence in our ability to continue to deliver on our strategy and vision. The progress we have made over the past several years is showing up in our results, and we remain focused on driving sustained, profitable growth as we head into Q4 and FY27."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。